Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 108.

https://doi.org/10.1182/blood-2023-180858

Published: 2023

Journal Articles

Bone Mineral Densitometry Diagnostic Yield Remains High Beyond 10 Years Post Allogeneic Stem Cell Transplant

Megan Hogg, Jacinta Perram, Abir Bhattacharyya, Ian Bilmon, Emily Blyth, John Kwan, Kenneth P. Micklethwaite, Shyam Panicker, Amanda Seabrook, David J Gottlieb

Blood (2022) 140 (Supplement 1): 7680–7681.

https://doi.org/10.1182/blood-2022-159843

Published: 2022

Journal Articles

Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control

Wei Jiang, Gaurav Sutrave, Selmir Avdic, Leighton Edward Clancy, Shafqat Inam, Elissa Atkins, Caroline M Bateman, Adrian Gabriel Selim, Vicki Antonenas, Janine Street, Renee Simms, Peter J. Shaw, David Ritchie, Emily Blyth, David J Gottlieb

Blood (2021) 138 (Supplement 1): 255.

https://doi.org/10.1182/blood-2021-152396

Published: 2021

Journal Articles

A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3 -ITD and CBL -Mutant Acute Myeloid Leukemia (PON-AZA study)

David Kipp, Sun Loo, Andrew Charles Perkins, Steven W Lane, Emily Blyth, Anoop Kumar Enjeti, Ashish Bajel, John Reynolds, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2021-154247

Published: 2021

Journal Articles

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac -modified CD19 CAR T cells

Blood (2021) 138 (16): 1504–1509.

https://doi.org/10.1182/blood.2021010813

Published: 2021

Includes: Supplemental data

Journal Articles

Investigation of product-derived lymphoma following infusion of piggyBac -modified CD19 chimeric antigen receptor T cells

Blood (2021) 138 (16): 1391–1405.

https://doi.org/10.1182/blood.2021010858

Published: 2021

Includes: Supplemental data

Journal Articles

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Wei Jiang, MBBS, M Clin MD FRACP, FRCPA, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Peter J. Shaw, MA,FRACP, Leighton Edward Clancy, BSc, PhD, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Abir Bhattacharyya, MBBS, FRACP, FRCPA, Elissa Atkins, RN, Selmir Avdic, PhD, Gaurav Sutrave, MBBS, FRACP, FRCPA, Janine Street, BSc MSc (Hons), David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-143136

Published: 2020

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

Journal Articles

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Leighton Edward Clancy, PhD, Elissa Atkins, GIllian Huang, David Collins, David Bishop, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2018-99-117417

Published: 2018

Journal Articles

Generation of Fungus-Specific T Lymphocytes for Use in HSCT Patients with Invasive Fungal Disease

Gloria Castellano Gonzalez, PhD, Emily Blyth, Leighton Clancy, BSc PhD, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 3186.

https://doi.org/10.1182/blood.V130.Suppl_1.3186.3186

Published: 2017

Journal Articles

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Emily Blyth, Barbara Withers, Leighton Edward Clancy, PhD, Agnes S. M. Yong, MDPhD, Christopher Fraser, MD, Jane Burgess, Renee Simms, Gloria Castellano Gonzalez, PhD, David Kliman, MBBS, Ming-Celine Dubosq, MD, David Bishop, Gaurav Sutrave, MBBS,, Chun Kei Kris Ma, PhDMBBS, Peter J. Shaw, MA,FRACP, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1919.

https://doi.org/10.1182/blood.V130.Suppl_1.1919.1919

Published: 2017

Journal Articles

Mass Cytometry Reveals the Broad Effect of CMV Reactivation on Adaptive and Innate Immune Recovery in HSCT Patients Undergoing Adoptive T Cell Therapy for Viral Infections

Emily Blyth, Helen Mcguire, Simone Rizzetto, Barbara Withers, Leighton Clancy, BSc PhD, Fabio Luciani, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 4501.

https://doi.org/10.1182/blood.V130.Suppl_1.4501.4501

Published: 2017

Journal Articles

Infusion of Unrelated-Donor Partially HLA-Matched Cells Results in Detectable Microchimerism in Patients with Acute Myeloid Leukemia: Early Post-Infusion Reactions Are Common but Self-Limiting

David Kliman, MBBS FRACP FRCPA, Emily Blyth, MBBS PhD FRACP FRCPA, Kenneth Yehson, BSc, Vicki Antonenas, BSc MSc, Leighton Clancy, PhD, John Kwan, MBBS FRACP FRCPA, Michael Haeusler, BSc, David Ritchie, MD PhD, David Gottlieb, MBBS MD FRACP FRCPA

Blood (2016) 128 (22): 3405.

https://doi.org/10.1182/blood.V128.22.3405.3405

Published: 2016

Journal Articles

Third-Party Donor Virus-Specific T Cells Are Efficacious in the Treatment of Refractory Viral Infection Following Allogeneic HSCT, but May Not Persist Post-Infusion

Barbara Withers, MBBS, Emily Blyth, MBBS, PhD, Leighton Clancy, PhD, Jane Burgess, Renee Simms, Kenneth Micklethwaite, MBBS, PhD, David Gottlieb, MBBS, MD

Blood (2015) 126 (23): 623.

https://doi.org/10.1182/blood.V126.23.623.623

Published: 2015

Journal Articles

Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection

Leighton Edward Clancy, PhD, Emily Blyth, Barbara Withers, Jane Burgess, Renee Simms, Chun Kei Kris Ma, B.Sc (MD MB BS FRACP FRCPA, Kenneth P. Micklethwaite, MD PhD, David Gottlieb, MB MDFRCPA FRACP

Blood (2014) 124 (21): 3835.

https://doi.org/10.1182/blood.V124.21.3835.3835

Published: 2014

Journal Articles

Prophylactic Infusion Of Multi-Virus Specific T Cells For Management Of Viral Reactivation and Infection In Patients Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Chun Kei Kris Ma, B.Sc (Med) MB BS FRACP FRCPA, Emily Blyth, Leighton Clancy, Renee Simms, Jane Burgess, Kenneth P. Micklethwaite, MD, PhD, David Gottlieb, MB, PhD, FRCPA, FRACP

Blood (2013) 122 (21): 4498.

https://doi.org/10.1182/blood.V122.21.4498.4498

Published: 2013

Journal Articles

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

Emily Blyth, Leighton Clancy, Renee Simms, Chun K. K. Ma, Jane Burgess, Shivashni Deo, Karen Byth, Ming-Celine Dubosq, Peter J. Shaw, Kenneth P. Micklethwaite, David J. Gottlieb

Blood (2013) 121 (18): 3745–3758.

https://doi.org/10.1182/blood-2012-08-448977

Published: 2013

Journal Articles

In Vitro Generation of Influenza-Virus Specific T Cells for Adoptive Immunotherapy,

Shiva Gaundar, Emily Blyth, Leighton Clancy, Renee Simms, David Gottlieb, MB

Blood (2011) 118 (21): 4040.

https://doi.org/10.1182/blood.V118.21.4040.4040

Published: 2011

Journal Articles

Cytotoxic T Cells Specific for Adenovirus, BK Virus, Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus Produced for Clinical Use In Immune Reconstitution Post Allogeneic Stem Cell Transplantation

Emily Blyth, Leighton Clancy, Shiva Gaundar, Renee Simms, David Gottlieb

Blood (2010) 116 (21): 830.

https://doi.org/10.1182/blood.V116.21.830.830

Published: 2010

Journal Articles

Epstein-Barr Virus Specific Cytotoxic T Cells for Clinical Use in Immune Reconstitution Post Haemopoietic Stem Cell Transplant.

Emily Blyth, B., Med, (Hons), FRACP, FRCPA, Leighton E Clancy, Upinder Sandher, Rajiv Khanna, BSc, MSc, PhD, David J Gottlieb

Blood (2009) 114 (22): 2435.

https://doi.org/10.1182/blood.V114.22.2435.2435

Published: 2009

NARROW

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Bone Mineral Densitometry Diagnostic Yield Remains High Beyond 10 Years Post Allogeneic Stem Cell Transplant

Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control

A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3 -ITD and CBL -Mutant Acute Myeloid Leukemia (PON-AZA study)

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac -modified CD19 CAR T cells

Investigation of product-derived lymphoma following infusion of piggyBac -modified CD19 chimeric antigen receptor T cells

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

Co-Administration of 3 rd party Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation

Generation of Fungus-Specific T Lymphocytes for Use in HSCT Patients with Invasive Fungal Disease

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Mass Cytometry Reveals the Broad Effect of CMV Reactivation on Adaptive and Innate Immune Recovery in HSCT Patients Undergoing Adoptive T Cell Therapy for Viral Infections

Infusion of Unrelated-Donor Partially HLA-Matched Cells Results in Detectable Microchimerism in Patients with Acute Myeloid Leukemia: Early Post-Infusion Reactions Are Common but Self-Limiting

Third-Party Donor Virus-Specific T Cells Are Efficacious in the Treatment of Refractory Viral Infection Following Allogeneic HSCT, but May Not Persist Post-Infusion

Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection

Prophylactic Infusion Of Multi-Virus Specific T Cells For Management Of Viral Reactivation and Infection In Patients Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

In Vitro Generation of Influenza-Virus Specific T Cells for Adoptive Immunotherapy,

Cytotoxic T Cells Specific for Adenovirus, BK Virus, Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus Produced for Clinical Use In Immune Reconstitution Post Allogeneic Stem Cell Transplantation

Epstein-Barr Virus Specific Cytotoxic T Cells for Clinical Use in Immune Reconstitution Post Haemopoietic Stem Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only